Seyed Morteza Ali Pourfaraji

Seyed Morteza Ali Pourfaraji

Auto-generated profile, based on publicly available information

Seyed Morteza Ali Pourfaraji

Faculty of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
PDParham Dastjerdi
Parham Dastjerdi
SPSeyed Morteza Pourfaraji
Seyed Morteza Pourfaraji
HSHedieh Shayesteh
Hedieh Shayesteh
MMMilad Maghsoudi
Milad Maghsoudi
SSSahar Saeidi
Sahar Saeidi
HSHamidreza Soleimani
Hamidreza Soleimani
By 2025, global obesity rates are projected to reach 16% in men and 21% in women, imposing a significant public health burden. Obesity is a major contributor to hypertension (HTN), exacerbating cardiovascular risks. This review and meta-analysis evaluated the effectiveness of non-surgical treatments versus bariatric surgery in managing hypertension among obese individuals. We searched PubMed, Scopus, Embase, and Cochrane databases up to May 2024. Randomized controlled trials (RCTs) comparing bariatric surgery (e.g., Roux-en-Y Gastric Bypass (RYGB), Sleeve gastrectomy (SG), Laparoscopic adjustable gastric banding (LAGB), Duodenal-jejunal bypass liner/Biliopancreatic diversion (DJBL/BPD)) with non-surgical interventions (e.g., lifestyle modifications, medications) in hypertensive obese patients were included. Primary outcomes were changes in systolic and diastolic blood pressure. Secondary outcomes included changes in fasting blood sugar (FBS), HbA1c, and lipid profiles. Data were synthesized using a random-effects model, with heterogeneity and publication bias assessed. From 7,187 records, 29 studies involving 2,548 patients met the inclusion criteria. Bariatric surgery resulted in greater reductions in systolic (MD: -4.506 mmHg; 95% CI: -6.999 to -2.013) and diastolic (MD: -3.040 mmHg; 95% CI: -4.765 to -1.314) blood pressure compared to non-surgical interventions. Roux-en-Y gastric bypass had the most significant impact. Bariatric surgery also led to substantial reductions in FBS (MD: -30.444 mg/dl; 95% CI: -41.288 to -19.601), HbA1c (MD: -1.108%; 95% CI: -1.414 to -0.802), and triglycerides (MD: -39.746 mg/dl; 95% CI: -54.458 to -25.034), and increased HDL levels (MD: 7.387 mg/dl; 95% CI: 5.056 to 9.719). The quality of evidence was high for most outcomes, supporting these findings. Bariatric surgery is superior to non-surgical treatments in managing obesity-related hypertension and metabolic disorders. Reductions in blood pressure, glycemic indexes, and lipid profiles highlight bariatric surgery’s critical role in improving cardiovascular health and metabolic outcomes in obese hypertensive patients.

12 July 2025 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Closed access
MKMehdi Karimi
Mehdi Karimi
NBNazgol Bahreini
Nazgol Bahreini
SPSamira Pirzad
Samira Pirzad
SPSeyed Morteza Ali Pourfaraji
Seyed Morteza Ali Pourfaraji
NSNiyusha Shirsalimi
Niyusha Shirsalimi
BLBagher Larijani
Bagher Larijani

15 May 2025 in International Journal of Cardiology Cardiovascular Risk and Prevention
Verified
Journal Article
Open access
MKMehdi Karimi
Mehdi Karimi
SPSamira Pirzad
Samira Pirzad
FHFarnaz Hooshmand
Farnaz Hooshmand
NSNiyousha Shirsalimi
Niyousha Shirsalimi
SPSeyed Morteza Ali Pourfaraji
Seyed Morteza Ali Pourfaraji
Coenzyme Q10 is a naturally occurring antioxidant that has been suggested to improve cardiovascular health. Studies examining the effects of Q10 on blood pressure (BP) and heart rate (HR) have found inconsistent results. This meta-analysis aims to clarify the effects of Q10 administration on BP and HR in adults. A comprehensive search of online databases was conducted until February 2025 to identify relevant randomized controlled trials (RCTs). Following screening, relevant data were extracted from the eligible studies. Statistical analyses were conducted using weighted mean differences (WMD) with 95 % confidence intervals (CI). Data analysis was performed using the "meta" package in R. The pooled analysis of 45 RCTs (48 effect sizes) showed that Q10 administration significantly reduced systolic BP (WMD: −3.44 mmHg; 95 %CI: [-5.13 to −1.55], p < 0.01), while no significant effect was observed on diastolic BP (WMD: −1.13 mmHg; 95 %CI: [-2.16 – 0.50], p = 0.23) and HR (WMD: −0.10 bpm; 95 %CI: [-2.09 – 1.89], p = 0.44). Subgroup analysis indicated that lower doses (8 weeks) resulted in greater systolic BP reductions. This meta-analysis indicates that CoQ10 supplementation may be an effective adjunctive therapy for reducing systolic blood pressure, especially at doses below 200 mg/day and with longer treatment durations. However, its impact on diastolic blood pressure and heart rate appears minimal. Given its favorable safety profile, CoQ10 could be considered as a supportive option in the management of hypertension, particularly for patients seeking non-pharmacological interventions or those with mild elevations in systolic BP.

24 July 2025 in Comprehensive Psychoneuroendocrinology
Verified
Journal Article
Open access
MKMehdi Karimi
Mehdi Karimi
FKFatemeh Ziyafati Kafi
Fatemeh Ziyafati Kafi
SPSamira Pirzad
Samira Pirzad
SPSeyed Morteza Ali Pourfaraji
Seyed Morteza Ali Pourfaraji
SJSharareh Jahangiri
Sharareh Jahangiri
Emerging evidence suggests Antipsychotics may influence cancer risk through prolactin elevation. While studies have explored the potential link between antipsychotic use and breast cancer risk, findings remain inconsistent. A comprehensive synthesis of existing data is needed to clarify this association. This meta-analysis aimed to discover the association between antipsychotic use and the risk of breast cancer in females. A comprehensive literature search was conducted across major online databases from inception to May 2025 to identify relevant studies. Data were extracted from eligible publications, and meta-analyses were performed to estimate the pooled effect sizes. Relative risks (RRs) were used for cohort studies, while odds ratios (ORs) were used for case-control studies. A pooled analysis of 13 observational studies (14 effect sizes from seven cohort and seven case-control studies) demonstrated a significant association between antipsychotic use and increased breast cancer risk (OR: 1.23; 95 % CI: 1.12-1.35; p < 0.01). Subgroup analyses showed elevated risk in both cohort studies (OR: 1.25; 95 % CI: 1.00-1.56; p = 0.046) and case-control studies (OR: 1.21; 95 % CI: 1.11-1.32; p < 0.001). First-generation antipsychotics were associated with a higher risk (OR: 1.22; 95 % CI: 1.03-1.45; p = 0.023) compared to second-generation agents (OR: 1.08; 95 % CI: 1.04-1.13; p < 0.001). Geographically, the highest risk was observed in Asian populations (OR: 1.42; 95 % CI: 1.08-1.88; p = 0.011), followed by European (OR: 1.21; 95 % CI: 1.14-1.28; p < 0.001) and North American populations (OR: 1.17; 95 % CI: 1.06-1.31; p = 0.002). This meta-analysis found that antipsychotic use is associated with a 23 % increased risk of breast cancer in females, with a higher risk observed for first-generation compared to second-generation antipsychotics, and particularly elevated in Asian populations. These findings emphasize the need for further research into the underlying mechanisms and regional disparities. Clinicians should carefully evaluate the risks when prescribing antipsychotics and consider regular breast health monitoring for patients undergoing long-term treatment.

22 January 2026 in Current Therapeutic Research
Verified
Journal Article
Open access
MKMehdi Karimi
Mehdi Karimi
SPSeyed Morteza Ali Pourfaraji
Seyed Morteza Ali Pourfaraji
PRPeyvand Parhizkar Roudsari
Peyvand Parhizkar Roudsari
SPSamira Pirzad
Samira Pirzad
Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to cardiometabolic abnormalities. Orlistat has demonstrated potential benefits on metabolic parameters, yet its efficacy in MASLD remains unclear. This meta-analysis aimed to assess the effects of Orlistat on cardiometabolic indices in patients with MASLD. To identify relevant randomized controlled trials (RCTs), a comprehensive search was conducted across major databases from inception to January 2026. Outcomes assessed included aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), triglycerides (TG), total cholesterol (TC), low- and high-density lipoprotein cholesterol (LDL-C, HDL-C), fasting blood glucose (FBG), fasting insulin (FI), homeostatic model assessment for insulin resistance (HOMA-IR), body mass index (BMI), systolic and diastolic blood pressure (BP). Pooled effect sizes were calculated using a random-effects model using weighted mean differences (WMD) with 95% confidence intervals (CI). Six RCTs were included in this meta-analysis. The pooled analysis showed that Orlistat significantly improved liver enzymes, with reductions in AST (WMD: −4.01 U/L, 95% CI: −6.05 to −1.97, P = 0.005), ALT (WMD: −8.70 U/L, 95% CI: −16.51 to −0.90, P = 0.036), and GGT (WMD: −7.74 U/L, 95% CI: −14.88 to −0.59, P = 0.04). It also improved lipid profile by lowering LDL-C (WMD: −5.61 mg/dL, 95% CI: −7.36 to −3.86, P = 0.002) and increasing HDL-C in long-term interventions (≥24 months, WMD: 1.65 mg/dL, 95% CI: 0.95–2.36, P = 0.02). Glycemic markers improved, with significant reductions in FBS (WMD: −4.05 mg/dL, 95% CI: −6.32 to −1.78, P = 0.005), FI (WMD: −2.50 μU/mL, 95% CI: −3.46 to −1.55, P = 0.003), and HOMA-IR (WMD: −0.70, 95% CI: −0.98 to −0.41, P = 0.004). Orlistat did not significantly affect BP. BMI decreased significantly overall (WMD: −0.99 kg/m², 95% CI: −1.18 to −0.81, P < 0.001), with stronger effects in long-term interventions. Orlistat may improve cardiometabolic and liver function in MASLD patients, significantly reducing liver enzymes, enhancing lipid profiles, improving glycemic control, and lowering BMI. These results indicate its potential as an effective therapeutic option for metabolic management. However, larger, high-quality RCTs with longer follow-up are necessary to confirm its long-term efficacy and safety.

21 June 2026 in Cancer Reports
Verified
Journal Article
Open access
SPSeyed Morteza Pourfaraji
Seyed Morteza Pourfaraji
AAAlireza Abdollahi
Alireza Abdollahi
FSFatemeh Ojaghi Shirmard
Fatemeh Ojaghi Shirmard
RGReza Ghalehtaki
Reza Ghalehtaki
SSSamaneh Salarvand
Samaneh Salarvand
Aim: This systematic review and meta‐analysis aimed to clarify the prognostic impact of human epidermal growth factor receptor 2 (HER2) overexpression on overall survival (OS) and progression‐free survival (PFS) in advanced and resectable gastric cancer. Methods: We systematically searched electronic databases for studies reporting survival outcomes associated with HER2 overexpression in gastric cancer patients. Hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) were pooled using random‐effects models. Results: A total of 39 studies with 19 903 gastric cancer patients were included. The pooled rate of HER2 overexpression was estimated at 16% (95% CI, 14% to 18%). Our analysis revealed that HER2 overexpression was significantly associated with worse OS (HR = 1.30, 95% CI 1.12 to 1.51; p < 0.01) and PFS (HR = 1.57, 95% CI: 1.09 to 2.26; p < 0.01). The association with worse OS was significant across the studies with resectable (HR = 1.31, 95% CI: 1.08 to 1.60; p < 0.01) and advanced (HR = 1.25, 95% CI: 1.00 to 1.58; p = 0.04) gastric cancer patients. However, the association between HER2 and PFS was only significant in the resectable subgroups (HR = 2.28, 95% CI: 1.09 to 4.74; p < 0.01), not in the advanced subgroup (HR = 1.18, 95% CI: 0.93 to 1.51; p = 0.16). Conclusions: HER2 overexpression appears to be associated with poorer outcomes in advanced and resectable gastric cancer. Standardizing diagnostic criteria and integrating HER2 assessment into multimarker panels could enhance prognostic accuracy and guide personalized therapeutic decisions.